Cargando…

Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia

Detalles Bibliográficos
Autores principales:	Niscola, Pasquale, Tendas, Andrea, Merola, Roberta, Orlandi, Giulia, Scaramucci, Laura, de Fabritiis, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595586/ https://www.ncbi.nlm.nih.gov/pubmed/26457287 http://dx.doi.org/10.5045/br.2015.50.3.181

Ejemplares similares

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
por: Tendas, Andrea, et al.
Publicado: (2014)

Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
por: Niscola, Pasquale, et al.
Publicado: (2015)

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab
por: Tendas, Andrea, et al.
Publicado: (2016)

PB2033: ADVANCED CHRONIC MYELOMONOCYTIC LEUKEMIA IN ELDERLY AND FRAIL PATIENTS MANAGED BY AZACITIDINE IN THE FIELD OF CLINICAL PRACTICE.
por: Niscola, Pasquale, et al.
Publicado: (2023)

Fever of unknown origin, anemia and thrombocytosis as early symptoms and signs of a late-onset polymialgia rheumatica: A diagnostic challenge
por: Niscola, Pasquale, et al.
Publicado: (2012)

IgA-induced autoimmune hemolytic anemia in a patient with antiphospholipid syndrome
por: Scaramucci, Laura, et al.
Publicado: (2012)

Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia
por: Scaramucci, Laura, et al.
Publicado: (2013)

Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency
por: Scaramucci, Laura, et al.
Publicado: (2016)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Primary mixed-type autoimmune hemolytic anemia concomitant with acute splanchnic venous thrombosis of idiopathic origin in a young woman: an unexplained association
por: Scaramucci, Laura, et al.
Publicado: (2013)

Idiopathic thrombocytopenic purpura coexisting with polycythemia vera
por: Niscola, Pasquale, et al.
Publicado: (2011)

Managing myelodysplastic syndromes in very old patients: a teaching case report
por: Niscola, Pasquale, et al.
Publicado: (2013)

Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?
por: Palombi, Massimiliano, et al.
Publicado: (2016)

Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin
por: Niscola, Pasquale, et al.
Publicado: (2012)

Pain in Blood Cancers
por: Niscola, Pasquale, et al.
Publicado: (2011)

Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
por: Niscola, Pasquale, et al.
Publicado: (2013)

Cold autoimmune hemolytic anemia resolved by rituximab
por: Palombi, Massimiliano, et al.
Publicado: (2010)

Authors’ Reply
por: Tendas, Andrea, et al.
Publicado: (2011)

Anticoagulant and Anti-thrombotic Treatments in the Management of Hematological Malignancies in a Home Care Program
por: Tendas, Andrea, et al.
Publicado: (2011)

Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis
por: Niscola, Pasquale, et al.
Publicado: (2013)

Pure erythroid leukemia in advanced breast cancer
por: Niscola, Pasquale, et al.
Publicado: (2014)

Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia
por: Čemažar, Luka, et al.
Publicado: (2020)

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
por: Islam, Anwarul
Publicado: (2023)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia
por: Morimoto, Yuki, et al.
Publicado: (2022)

Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism
por: Sethi, Sidharth Kumar, et al.
Publicado: (2018)

P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL
por: Ross, David, et al.
Publicado: (2023)

P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
por: Koenig, Kristin, et al.
Publicado: (2023)

Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
por: Gauchy, Anne‐Cécile, et al.
Publicado: (2020)

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature
por: Elli, Elena, et al.
Publicado: (2012)

Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
por: Nakako, Soichiro, et al.
Publicado: (2021)

Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial
por: Morita, Yasuyoshi, et al.
Publicado: (2018)

Management of Peritoneal Dialysis within a Home Care Program for Hematological Malignancies: Concerns and Perspectives Illustrated by a Case Report
por: Vischini, Gisella, et al.
Publicado: (2011)

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Homecare-based Motor Rehabilitation in Musculoskeletal Chronic Graft Versus Host Disease
por: Tendas, A, et al.
Publicado: (2011)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
por: Molica, Matteo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iqu8i64elhi1hdnlg107bcrjl4